Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 held today i.e. 14th November, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Bio Systems' board met on 14 November 2025 and approved standalone unaudited financial results for the quarter and half year ended 30 September 2025. For Q2 FY26, revenue from operations stood at Rs. 24.47 lakhs with a profit after tax of Rs. 3.94 lakhs (EPS Rs. 0.06), up from Rs. 18.05 lakhs in Q1 FY26. For H1 FY26, total income was Rs. 42.52 lakhs and profit after tax was Rs. 7.95 lakhs (EPS Rs. 0.11), a clear turnaround from a loss of Rs. 0.50 lakhs in H1 FY25. The board also appointed Mr. Shashank Kumar (M/s Shashank Kumar & Associates) as Secretarial Auditor and Mr. Nishant Sharma (M/s Vyom Advisors) as Internal Auditor, both for FY 2025-26. The statutory auditor (Sunit M Chhatbar & Co) issued an unqualified limited review report with no material misstatements flagged. Total assets stood at Rs. 1,526.61 lakhs as on 30 Sep 2025, with shareholder funds of Rs. 598.40 lakhs and reserves still in the negative at Rs. (101.82) lakhs.
The company has returned to profit on a year-on-year basis after a loss-making FY25, but the absolute earnings size is very small and reserves remain negative, signalling a micro-cap turnaround story rather than a strong fundamental shift. Auditor appointments are routine compliance items, so the main watch point for investors will be whether the H2 FY26 earnings momentum sustains the recovery.